Yes. Not only do they exist in great similarity to the zebrafish, CRATERs multiply during successful immunotherapy- when the patient presented clinical benefit post treatment. But there are extremely few CRATERs when treatment failed, even if the T cells entered the tumor.
October 18, 2025 at 5:46 PM
Everybody can reply
1 likes
It is in the CRATERs that we find multiple, lasting interactions of CD8+ T cells and melanoma, cell death, IFN-γ production. A battlefield. Indicating that the CRATERs are a major site for tumor killing following immunotherapy. Now the big question is- in human melanoma too?
October 18, 2025 at 5:46 PM
Everybody can reply
1 likes
Without treatment, CD8+ T cells don't harm tumors too much. But immunotherapy is aimed at activating CD8+ T cells against tumors. When we give immunotherapy these pockets–CRATERs; Cancer Regions of Antigen presentation and T cell engagement and Retention- come alive.
October 18, 2025 at 5:46 PM
Everybody can reply
1 likes
Immunotherapy may fail to create an efficient anti-tumor immune response. Even when CD8+ T cells do infiltrate the tumor. The approach we took was to look closely at CD8+ T cells behavior within melanoma tumor, to understand how to recognize an efficient anti-immune response.
October 18, 2025 at 5:46 PM
Everybody can reply
1 likes
What’s it about? You can activate CD8+ T cells against tumors and get them to kill it. This notion was developed into immunotherapy and has saved many lives to date (and won a Nobel prize). But it doesn’t always work.
October 18, 2025 at 5:46 PM
Everybody can reply
1 likes
🚨Publication alert: Where does immunotherapy happen? What can the fish teach us about human pathology? And a dendritic cell is having a friend for dinner. Cancer immunology goes live, now in @cp-cell.bsky.social.
Here is a concise summary of a pretty big study 🧵. Let’s go (appetizer👇)
Here is a concise summary of a pretty big study 🧵. Let’s go (appetizer👇)
October 18, 2025 at 5:46 PM
Everybody can reply
1 reposts
1 quotes
5 likes
Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
October 18, 2025 at 5:08 PM
Everybody can reply
#ESMO25 | Uveal melanoma: positive results of the phase 2 PLUME clinical trial, presented by Dr. Manuel Rodrigues @institutcurie.bsky.social (efficacy and tolerability of immunotherapy anti-PD-1 + targeted treatment)
➡️ Learn more:
institut-curie.org/news/metasta...
#medonc #oncalert
➡️ Learn more:
institut-curie.org/news/metasta...
#medonc #oncalert
October 18, 2025 at 4:56 PM
Everybody can reply
I’m a total uninitiate, following the frontiers of medical research is a hobby stroke passing interest of mine. My father has been an on-again-off-again community advocate for accelerating immunotherapy trials in people and it chuffs me to know more about the avant garde than him!
October 18, 2025 at 4:22 PM
Everybody can reply
1 likes
#ESMO25: Clinically relevant survival benefits reported in platinum-resistant #OvarianCancer with pembrolizumab plus weekly paclitaxel with or without bevacizumab in ENGOT-ov65/KEYNOTE-B96 #ESMODailyReporter 👉https://ow.ly/MIjA50XeuR3
#immunotherapy
#immunotherapy
October 18, 2025 at 4:01 PM
Everybody can reply
1 reposts
1 likes
New study suggests #omalizumab may help patients safely continue honeybee venom immunotherapy after severe allergic reactions.
Read more: www.hcplive.com/view...
#Allergy #Immunology # #VenomImmunotherapy
Read more: www.hcplive.com/view...
#Allergy #Immunology # #VenomImmunotherapy
Omalizumab May Improve Tolerance to Venom Immunotherapy | HCPLive
A new study found that adjunct omalizumab helped most patients safely continue honeybee venom immunotherapy after prior severe allergic reactions.
www.hcplive.com
October 18, 2025 at 4:00 PM
Everybody can reply
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study. ascopubs.org/doi/10.1200/...
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAF<sup>V600E</sup>-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study.
8574Background: Patients (pts) with BRAFV600E mutated non-small cell lung cancer (NSCLC) can be effectively treated with BRAF and
MEK inhibitors (BRAFi+MEKi) or with immune checkpoint inhibitors ± che...
ascopubs.org
October 18, 2025 at 2:54 PM
Everybody can reply
That concludes our live coverage of ‘Immunotherapy in NSCLC: Where are we now?’. Stay tuned for more expert commentary from #ESMO25 with insights from ‘Optimising management of localised bladder cancer’ starting at 15:30 BST/16:30 CEST
#Oncology #OncSky #MedSky #MedEd #LungCancer #NSCLC
#Oncology #OncSky #MedSky #MedEd #LungCancer #NSCLC
October 18, 2025 at 2:17 PM
Everybody can reply
1 reposts
1 likes
This just in! Laura Mezquita highlights the push toward smarter immune responses in advanced #NSCLC, with a focus on adoptive cell therapy and other emerging approaches. Her outlook? A future where #immunotherapy is personalized to each patient
#ESMO25 #Oncology #LungCancer #OncSky #MedSky #MedEd
#ESMO25 #Oncology #LungCancer #OncSky #MedSky #MedEd
October 18, 2025 at 2:15 PM
Everybody can reply
1 reposts
1 likes
Relatedly, when offering an immunotherapy to a metastatic patient, you must disclose the overall response rate, not just the overall survival benefit, and explain why ORR is so low when OS is high.
October 18, 2025 at 2:14 PM
Everybody can reply
🔹 Pr. @benjaminbessemd.bsky.social discussing on optimisation of dose schedule and duration of immunotherapy in NSCLC at @myesmo.bsky.social
#ESMO #ESMO25
#ESMO #ESMO25
October 18, 2025 at 1:59 PM
Everybody can reply
2 likes
🫁 @benjaminbessemd.bsky.social calls for a rethink on immunotherapy for #NSCLC, highlighting the need for de-escalation trials based on compelling biological and pharmacokinetic evidence. The idea is simple: sometimes, less might actually be more
#ESMO25 #Immunotherapy #LungCancer #Oncology
#ESMO25 #Immunotherapy #LungCancer #Oncology
October 18, 2025 at 1:55 PM
Everybody can reply
1 reposts
3 likes
Why it matters: Making “cold” tumors “hot.”
Increased antigen presentation = tumors more visible to the immune system, potentially improving immunotherapy responses—an actionable combo-therapy lead.
Paper: www.biorxiv.org/content/10.1...
Increased antigen presentation = tumors more visible to the immune system, potentially improving immunotherapy responses—an actionable combo-therapy lead.
Paper: www.biorxiv.org/content/10.1...
Scaling Large Language Models for Next-Generation Single-Cell Analysis
Single-cell RNA sequencing has transformed our understanding of cellular diversity, yet current singlecell foundation models (scFMs) remain limited in their scalability, flexibility across diverse tas...
www.biorxiv.org
October 18, 2025 at 1:53 PM
Everybody can reply
Who shouldn’t get #immunotherapy? Joachim Aerts says no group should be ruled out, but stresses “do no harm.” It’s about using it where it truly makes a difference, not applying it across the board. A thoughtful take on a complex and ever-evolving topic.
#ESMO25 #Oncology #OncSky #MedSky
#ESMO25 #Oncology #OncSky #MedSky
October 18, 2025 at 1:43 PM
Everybody can reply
1 reposts
1 likes
🔬 @solangepeters.bsky.social opens with insights on optimising patient selection for immunotherapy using clinical features like smoking history, gender, and brain metastases, plus tumour characteristics like histology and biomarkers. Real-world relevance is key.
#ESMO25 #Immunotherapy #LungCancer
#ESMO25 #Immunotherapy #LungCancer
October 18, 2025 at 1:24 PM
Everybody can reply
1 reposts
1 likes
We’re back this afternoon with more LIVE coverage of #ESMO25! Follow along for updates from today’s session ‘Immunotherapy of NSCLC: Where are we now?’ for the latest insights on lung cancer care
#Oncology #OncSky #MedSky #MedEd #LungCancer #NSCLC
#Oncology #OncSky #MedSky #MedEd #LungCancer #NSCLC
October 18, 2025 at 12:44 PM
Everybody can reply
1 reposts
1 likes
Results from a trial found a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma whose disease progressed following immunotherapy.
Learn more about the data presented at #ESMO25: www.mdanderson.org/newsroom/res... #EndCancer
Learn more about the data presented at #ESMO25: www.mdanderson.org/newsroom/res... #EndCancer
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression First head-to-head study comparing second-line treatments lenvatinib plus everolimus vs.
www.mdanderson.org
October 18, 2025 at 12:04 PM
Everybody can reply
1 likes
The first day of poster presentations at
#ESMO25 featured some of our expert's insights into topics from the impact of genomic alterations to results from a phase Ill trial of immunotherapy responders.
#ESMO25 featured some of our expert's insights into topics from the impact of genomic alterations to results from a phase Ill trial of immunotherapy responders.
October 18, 2025 at 11:55 AM
Everybody can reply
2 likes
Lisa O'Neil presents the practical and logistical challenges and potential solutions to switching from IV to SC immunotherapy. Extra 'Brownie points' for quoting from our paper. @ukons.bsky.social #ESMO25 #EONS18 @marytanay.bsky.social
October 18, 2025 at 10:58 AM
Everybody can reply
1 reposts
2 likes
This common liver supplement could supercharge cancer treatment! Scientists say bile acids might hold the key to making liver cancer immunotherapy finally work. #TCSC #CancerResearch #Immunotherapy #LiverCancer #MedicalBreakthrough
www.sciencedaily.com/releases/202...
www.sciencedaily.com/releases/202...
This common liver supplement could boost cancer treatment success
Salk Institute scientists discovered that bile acids in the liver can weaken immune cell function, making immunotherapy less effective against liver cancer. They pinpointed specific bile acids that su...
www.sciencedaily.com
October 18, 2025 at 10:38 AM
Everybody can reply